 | Up a level |
2022
Tan, Daniel S. W., Kim, Sang-We, Aix, Santiago Ponce, Sequist, Lecia, V, Smit, Egbert F., Yang, James C. H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohe, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2022). Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur. J. Cancer, 172. S. 276 - 287. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2020
Tan, Daniel Shao-Weng, Leighl, Natasha B., Yang, James Chih-Hsin, Riely, Gregory J., Sequist, Lecia, V, Toyozawa, Ryo, Wolf, Juergen, Felip, Enriqueta, Kim, Sang-We, Aix, Santiago Ponce, Smit, Egbert F., Hida, Toyoaki, Grohe, Christian, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2020). Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755